|
|
|
|
|
|
|
Illuminating biomarker detection – Leading the way in personalized medicine.
2011
EORTC/NCI/AACR Molecular Targets and Cancer Therapeutics – San Francisco, CA November 2011
Gupta V, et al. “EpCAM-Independent ApoStream Technology Isolates Circulating Tumor Cells from Blood of Patients with Various Types of Cancer.”
Neal C, et al. “Measurement of CUDC-101 Target Inhibition in Circulating Tumor Cells Using a Fluorescent-Based, Quantitative Assay
EORTC/NCI/ASCO Molecular Markers in Cancer – Brussels, Belgium October 2011
Gupta V, et al. “Antibody-independent Enrichment of Live Circulating Tumor Cells (CTCs) from a Variety of Cancer Types.”
CHI’s ADAPT Conference – Philadelphia, PA September 2011
Melnikova V, et al. “Development of Allele-Specific PCR Assay for Detection of BRAF V600E Mutation in Circulating Tumor Cells.”
Gupta V, et al. “Antibody-independent Enrichment of Live Circulating Tumor Cells (CTCs) from a Variety of Cancer Types.”
AACR – Orlando, FL April 2011
Abstract #3159, Melnikova VO et. Al., “BRAFV600E mutation analysis in circulating tumor cells.”
Abstract #4155, Wu W, et. Al.,“Simultaneous quantification of multiple signaling molecules in individual circulating tumor cells (CTCs) by multi-color laser scanning cytometry.”
Biomarker Assay Development – San Diego, CA 2011
Melnikova VO et. Al.,“BRAF V600E Mutation Allele- Specific PCR Assay in Circulating Tumor Cells.”
High Content Analysis – San Francisco, CA 2011
Wu W, A et. Al., “High Content Imaging and Characterization of Circulating Tumor Cells (CTC) from Cancer Patients.”
2010
EORTC/NCI/AACR Molecular Targets and Cancer Therapeutics – Berlin, Germany November 2010
Davis, DW et. Al.,“Molecular characterization of circulating tumor cells using a highly sensitive method of enrichment based on the cellsearch CTC profile kit.”
ESMO 2010 – Milan, Italy October 2010
Abstract #1335P, Eisen, A et. Al., “CTC Biomarker Assessment To Aid Dosing Selection of E6201, A Potent MEK1 Inhibitor, For Treatment Of BRAF-Mutated Melanoma.”
ASCO – Chicago, Illinois June 2010
Abstract #3093, Davis, DW et. Al., “Sensitive detection of gamma-H2AX induction as a pharmacodynamic marker for profiling patients with cancer treated with topotecan.”
Abstract #3040, Martin SF et. Al., “Treatment of VHL patients with sunitinib: Clinical outcomes and translational studies.”
AACR – Washington, D.C. April 2010
Abstract # 2687, Melnikova VO et. Al., “Development of a new, highly sensitive assay for circulating tumor cell (CTC) detection based on the CellSearch® CTC Profile Kit enrichment and laser scanning cytometry analysis”
2009
ASCO – Orlando, Florida May 2009
Abstract #3525, Davis, DW et. Al., “Circulating Tumor and Endothelial Cells as Pharmacodynamic Biomarkers in a Phase I Clinical Trial of Intravenous Bevacizumab in Combination with Escalating Doses of Oral Cediranib for Patients with Advanced Malignancies”
EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics – Boston, Massachusetts November 2009
Davis, DW et. Al., “Prospective Real-time Analysis of P-cadherin Expression to Select Patients into a Phase I Oncology Trial”
Abstract #7534, Davis, DW et. Al., “Phase 1 Trial of a Combination of the VEGFR KinaseInhibitor Cediranib(AZD2171) and Bevacizumab in Advanced Malignancies.”
2007
ASCO – Chicago, Illinois May 2007
Abstract #8021, Davis, DW, et. al., “pKDR/KDR ratio as possible predictor of response in Phase I/II study of erlotinib and bevacizumab for recurrent or metastatic Head and Neck Cancer”
EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics San Francisco, CA 2007
Abstract #C165, Davis, DW et. al.,”Predictive markers of response in a Phase I/II pharmacodynamic (PD) study of erlotinib and bevacizumab for recurrent or metastatic head and neck cancer (HNC)”.
2006
EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics – Prague, Czech Republic 2006
Abstract #57, Davis, DW et. al., “Correlation of receptor tyrosine kinase (RTK) activity and apoptosis with response to sunitinib treatment in patients with gastrointestinal stromal tumor (GIST)”.
ICACT Paris, France 2006
Abstract #A300, Davis, DW et. al., “Receptor tyrosine kinase activity and apoptosis as biomarkers of SU11248 (sunitinib malate) activity in patients with gastrointestinal stromal tumor”.
2005
EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics – Philadelphia, Pennsylvania 2005
Davis, DW, et. al., Receptor Tyrosine Kinase Activity and Apoptosis in Gastrointestinal Stromal Tumors: a Pharmacodynamic Analysis of Response to Sunitinib Malate (SU11248) Therapy.
ECCO Paris, France 2005
Abstract # 715, Davis, DW, et. al., Receptor tyrosine kinase activity and apoptosis in gastrointestinal stromal tumours: a pharmacodynamic analysis of response to sunitinib malate (SU11248) therapy. Oral Presentation.
ASCO – Orlando, Florida, May 2005
Abstract #3006, Davis, DW, et. al., “Pharmacodynamic Analysis of Target Receptor Tyrosine Kinase Activity and Apoptosis in GIST Responding to Therapy with SU11248″.
Abstract #9001, Trent JC, et. al., “Antivascular and apoptotic effects of imatinib in GIST”.
|
|
|
|
